IL1B and myocardial infarction: On the contrary, CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) demonstrated that IL-1β inhibitor canakinumab significantly reduced cardiovascular events in post-myocardial infarction patients with hsCRP levels ≥ 2 mg/L [33].